← All drugs
Drug · FAERS side-effect profile with label screen

Metformin Hydrochloride side effects: what 57,453 FDA adverse event reports show

Metformin Hydrochloride · Metformin Hydrochloride · 1,204 reaction terms · 247,296 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Metformin Hydrochloride

openFDA label

Who reports

57,453 reports · 73% serious · 5,658 with death outcome · 55% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )

FDA label, Indications and Usage

What it is

Metformin hydrochloride extended-release tablets, USP contain the biguanidine antihyperglycemic agent, metformin, in the form of monohydrochloride salt.

FDA label, Description section

Boxed warning

LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 1Labeled (related wording) 3Lab value / disease marker 4Not in label — unassessed 31
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,164 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Heart sounds40250.5
167.0–375.8ROR 250.7 · calibrated p 3e-10 ✓
137.1 EB05 105.0 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Pulmonary vasculitis11498.0
79.6–120.6ROR 98.2 · calibrated p 2e-7 ✓
75.9 EB05 64.9 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=114 · ♀ 0% (drug 55%)no trial arm names this drug
Neurologic neglect syndrome11390.1
73.3–110.7ROR 90.2 · calibrated p 3e-7 ✓
71.0 EB05 60.7 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=113 · ♀ 100% (drug 55%)no trial arm names this drug
Prolonged expiration4063.5
45.3–88.9ROR 63.5 · calibrated p 5e-6 ✓
52.6 EB05 40.3 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=40 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Total lung capacity abnormal5560.1
45.1–80.0ROR 60.1 · calibrated p 6e-6 ✓
50.6 EB05 40.3 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Hypocholesterolaemia4459.3
43.1–81.7ROR 59.4 · calibrated p 7e-6 ✓
49.9 EB05 38.7 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=44 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Human rhinovirus test positive5359.0
44.1–78.9ROR 59.1 · calibrated p 7e-6 ✓
49.8 EB05 39.5 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=53 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Capillaritis3858.7
41.6–82.8ROR 58.7 · calibrated p 9e-6 ✓
49.3 EB05 37.5 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=38 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Lactic acidosis4,53858.7
56.9–60.5ROR 63.5 · calibrated p 3e-6 ✓
50.4 EB05 49.2 · IC025 +5.6
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 47.2 · serious PRR 40.4 · 93% clinicianno trial arm names this drug
Carotid artery thrombosis11857.1
47.0–69.3ROR 57.2 · calibrated p 7e-6 ✓
48.9 EB05 41.9 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=118 · ♀ 100% (drug 55%)no trial arm names this drug
Alveolar osteitis5451.6
38.8–68.7ROR 51.6 · calibrated p 2e-5 ✓
44.5 EB05 35.4 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=53 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Urinary tract discomfort5650.2
38.0–66.5ROR 50.3 · calibrated p 2e-5 ✓
43.5 EB05 34.7 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=56 · ♀ 100% (drug 55%)no trial arm names this drug
Spirometry abnormal6544.3
34.2–57.3ROR 44.3 · calibrated p 4e-5 ✓
39.0 EB05 31.7 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=65 · ♀ 0% (drug 55%)no trial arm names this drug
Cerebral hypoperfusion4942.5
31.6–57.2ROR 42.6 · calibrated p 5e-5 ✓
37.5 EB05 29.5 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=49 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Adjustment disorder11835.4
29.3–42.7ROR 35.4 · calibrated p 1e-4 ✓
32.1 EB05 27.5 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=115 · ♀ 100% (drug 55%)no trial arm names this drug
Pneumonia haemophilus4233.6
24.4–46.0ROR 33.6 · calibrated p 2e-4 ✓
30.3 EB05 23.4 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=42 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Mite allergy5533.5
25.4–44.2ROR 33.6 · calibrated p 2e-4 ✓
30.4 EB05 24.2 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Respiratory syncytial virus test positive5429.5
22.3–38.9ROR 29.5 · calibrated p 4e-4 ✓
27.1 EB05 21.5 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=54 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Hypoglycaemic coma20326.8
23.3–31.0ROR 26.9 · calibrated p 5e-4 ✓
25.0 EB05 22.2 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=203no trial arm names this drug
Mycotic allergy5625.3
19.3–33.2ROR 25.3 · calibrated p 8e-4 ✓
23.5 EB05 18.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=56 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Neuritis10225.2
20.7–30.9ROR 25.3 · calibrated p 7e-4 ✓
23.5 EB05 19.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 0% (drug 55%)no trial arm names this drug
Hyperlactacidaemia17325.0
21.4–29.1ROR 25.0 · calibrated p 7e-4 ✓
23.3 EB05 20.5 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=173no trial arm names this drug
Antineutrophil cytoplasmic antibody positive4624.0
17.8–32.3ROR 24.0 · calibrated p 0.001 ✓
22.3 EB05 17.4 · IC025 +3.7
3/3 methods agree
Lab value / disease markerserious n=46 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Facet joint syndrome19924.0
20.8–27.7ROR 24.0 · calibrated p 9e-4 ✓
22.4 EB05 19.9 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=199 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Continuous haemodiafiltration6123.3
18.0–30.2ROR 23.3 · calibrated p 0.001 ✓
21.8 EB05 17.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=59 · 100% clinicianno trial arm names this drug
Animal scratch5722.2
17.0–29.0ROR 22.2 · calibrated p 0.001 ✓
20.8 EB05 16.7 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=57 · ♀ 100% (drug 55%)no trial arm names this drug
Dust allergy5521.5
16.4–28.2ROR 21.5 · calibrated p 0.002 ✓
20.2 EB05 16.1 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=55 · ♀ 0% (drug 55%) · 100% clinicianno trial arm names this drug
Bronchopulmonary aspergillosis allergic5221.4
16.2–28.3ROR 21.4 · calibrated p 0.002 ✓
20.1 EB05 15.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=52 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Ketosis5018.1
13.6–24.1ROR 18.1 · calibrated p 0.004 ✓
17.1 EB05 13.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=46 · 100% clinicianno trial arm names this drug
Personality disorder12718.0
15.1–21.5ROR 18.0 · calibrated p 0.003 ✓
17.1 EB05 14.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=127 · ♀ 100% (drug 55%)no trial arm names this drug
Peripheral venous disease19117.9
15.4–20.6ROR 17.9 · calibrated p 0.003 ✓
17.0 EB05 15.1 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=188 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Conjunctivitis allergic6917.6
13.8–22.4ROR 17.6 · calibrated p 0.004 ✓
16.7 EB05 13.6 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=69 · ♀ 0% (drug 55%)no trial arm names this drug
Metabolic acidosis1,42016.7
15.8–17.6ROR 17.1 · calibrated p 0.004 ✓
16.0 EB05 15.3 · IC025 +3.9
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 15.8 · serious PRR 12.9 · 91% clinicianno trial arm names this drug
Onychomadesis17916.0
13.8–18.6ROR 16.1 · calibrated p 0.005 ✓
15.3 EB05 13.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=177 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Onychomycosis18615.8
13.6–18.3ROR 15.8 · calibrated p 0.006 ✓
15.1 EB05 13.4 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Eosinophilic granulomatosis with polyangiitis8515.6
12.6–19.4ROR 15.6 · calibrated p 0.006 ✓
14.9 EB05 12.4 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=85 · ♀ 0% (drug 55%)no trial arm names this drug
Distributive shock9315.6
12.7–19.2ROR 15.6 · calibrated p 0.006 ✓
14.9 EB05 12.5 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=93 · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Hypoglycaemia1,9797.77.3–8.0signal
Kidney injury5,5084.44.3–4.6signal
Hyperglycaemia / diabetes4,0184.34.1–4.4signal
Pancreatitis6563.02.8–3.2signal
Rhabdomyolysis / myopathy5312.42.2–2.6signal
Hyponatraemia4942.22.1–2.5signal
Suicidality1,3952.12.0–2.2raised
Fall / fracture1,9481.91.8–2.0raised
Interstitial lung disease4891.91.7–2.0raised
Heart failure8791.81.7–1.9raised
Liver injury1,4581.81.7–1.9raised
Anaemia1,3461.61.6–1.7raised
Arrhythmia / qt8351.61.5–1.7raised
Depression1,1861.51.5–1.6raised
Serious infection3,2001.51.5–1.6raised
Stroke1,0301.51.4–1.6raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Metformin Hydrochloride (searched METFORMIN).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Lactic acidosis4,53858.7
56.9–60.5ROR 63.5 · calibrated p 3e-6 ✓
50.4 EB05 49.2 · IC025 +5.6
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 47.2 · serious PRR 40.4 · 93% clinicianno trial arm names this drug
Diarrhoea (diarrhea)4,4242.5
2.4–2.5ROR 2.6 · calibrated p 0.780
2.5 EB05 2.4 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 2.2no trial arm names this drug
Nausea3,5891.6
1.6–1.7ROR 1.7 · calibrated p 0.747
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Acute kidney injury (sudden kidney damage)3,2377.7
7.5–8.0ROR 8.1 · calibrated p 0.064
7.6 EB05 7.4 · IC025 +2.9
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 6.8 · serious PRR 6.0no trial arm names this drug
Fatigue (tiredness)3,1671.5
1.4–1.5ROR 1.5 · calibrated p 0.629
1.5 EB05 1.4 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.2 · serious PRR 1.4no trial arm names this drug
Drug ineffective (drug did not work)2,8160.8
0.7–0.8ROR 0.7 · calibrated p 0.156
0.8 EB05 0.7 · IC025 -0.5
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 1.0no trial arm names this drug
Vomiting2,6652.0
2.0–2.1ROR 2.1 · calibrated p 0.987
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 2.0no trial arm names this drug
Dyspnoea (shortness of breath)2,6571.7
1.6–1.7ROR 1.7 · calibrated p 0.775
1.7 EB05 1.6 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.5no trial arm names this drug
Headache2,3311.3
1.3–1.4ROR 1.3 · calibrated p 0.536
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.4no trial arm names this drug
Off label use (used outside approved label)2,2410.9
0.9–1.0ROR 0.9 · calibrated p 0.254
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.0no trial arm names this drug
Dizziness2,1641.6
1.5–1.6ROR 1.6 · calibrated p 0.689
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.6no trial arm names this drug
Asthenia (weakness)2,1142.0
1.9–2.1ROR 2.0 · calibrated p 0.969
2.0 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.7 · serious PRR 1.8no trial arm names this drug
Pain2,1021.2
1.2–1.3ROR 1.2 · calibrated p 0.458
1.2 EB05 1.2 · IC025 +0.2Labeled — boxed warning
exact term
age-adj. PRR 1.3 · serious PRR 1.1no trial arm names this drug
Fall1,9412.1
2.0–2.2ROR 2.1 · calibrated p 0.990
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 1.8no trial arm names this drug
Malaise (feeling unwell)1,8351.5
1.4–1.6ROR 1.5 · calibrated p 0.645
1.5 EB05 1.4 · IC025 +0.5Labeled — boxed warning
exact term
age-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Metformin ↔ Lactic acidosis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Metformin Hydrochloride?

In FDA FAERS, the most frequently co-reported reaction terms for Metformin Hydrochloride are lactic acidosis, diarrhoea, nausea, acute kidney injury, fatigue, vomiting. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Metformin Hydrochloride have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.

Do FAERS signals prove that Metformin Hydrochloride causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.